Corrigendum to: Psoriasis heritability: 125 years and counting (British Journal of Dermatology, (2014), 171, 1, (3-5), 10.1111/bjd.13105);Psoriasis heritability: 125 years and counting

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 3-5

  Barker, J ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FILAGGRIN; HLA C ANTIGEN; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; LEUKOCYTE ANTIGEN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACRODERMATITIS; ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; DIZYGOTIC TWINS; ECZEMA; FIRST DEGREE RELATIVE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC VARIABILITY; HERITABILITY; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; LINKAGE ANALYSIS; MONOZYGOTIC TWINS; PEDIGREE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TH17 CELL; TWIN CONCORDANCE; GENETIC PREDISPOSITION; GENETICS; HISTORY;

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PSORIASIS;

EID: 84904903396     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.17308     Document Type: Erratum

References (40)

1. Bunker C,. Henry Radcliffe Crocker. In: Pantheon of Dermatology. (, C Löser, W Burgdorf, G Plewig, eds), Berlin: Springer, 2013; 179-84.
2. Burton JL,. Diet and dermatology in 1888: the influence of H. Radcliffe Crocker. Br J Dermatol 1988; 119: 471-7.
3. Fry L,. Psoriasis. Br J Dermatol 1988; 119: 445-61.
4. Crocker HR,. Diseases of the Skin. Philadelphia, PA: P. Blakiston, 1893.
5. Henseler T, Christophers E,. Psoriasis of early and late onset: characterisation of two types of psoriasis. J Am Acad Dermatol 1985; 13: 450-6.
6. Lomholt G,. Psoriasis: Prevalence, Spontaneous Course and Genetics. Copenhagen: GEC GAD, 1963.
7. Farber E, Nall M, Watson W,. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974; 109: 207-11.
8. Tillikainen A, Lassus A, Karvonen J, et al,. Psoriasis and HLA-Cw6. Br J Dermatol 1978; 29: 303-12.
9. Valdimarsson H, Baker B, Jonsdottir I, Fry L,. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986; 7: 256-9.
10. Trembath RC, Clough RL, Rosbotham JL, et al,. Identification of a major susceptibility gene locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6: 813-20.
11. Tomfohrde J, Silverman A, Barnes A, et al,. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264: 1141-5.
12. Jordan CT, Cao L, Roberson EDO, et al,. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012; 90: 784-95.
13. Capon F, Novelli G, Semprini S, et al,. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 1999; 112: 32-5.
14. Manolio TA, Collins FS, Cox NJ, et al,. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-53.
15. Capon F, Burden AD, Trembath RC, Barker JN,. Psoriasis and other complex trait dermatoses: from loci to functional pathways. J Invest Dermatol 2012; 132: 915-22.
16. Tsoi LC, Spain SL, Knight J, et al,. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012; 44: 1341-8.
17. Quesada J, Gutterman J,. Psoriasis and alpha-interferon. Lancet 1986; 327: 1466-8.
18. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
19. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al,. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
20. de Cid R, Riveira-Muñoz E, Zeeuwen PL, et al,. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009; 41: 211-15.
21. Hollox EJ, Huffmeier U, Zeeuwen PL, et al,. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008; 40: 23-5.
22. Nestle FO, Conrad C, Tun-Kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43.
23. Allen MH, Ameen M, Veal C, et al,. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol 2005; 124: 103-7.
24. Hébert HL, Bowes J, Smith RL, et al,. Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. J Invest Dermatol 2013; 134: 1459-62.
25. Marrakchi S, Guigue P, Renshaw BR, et al,. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
26. Onoufriadis A, Simpson MA, Burden AD, et al,. Identification of rare, disease-associated variants in the promoter region of the RNF114 psoriasis susceptibility gene. J Invest Dermatol 2012; 132: 1297-9.
27. Berki DM, Mahil SK, David Burden A, et al,. Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris. J Invest Dermatol 2014; 134: 271-3.
28. Setta-Kaffetzi N, Simpson MA, Navarini AA, et al,. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 2014; 94: 790-7.
29. Viguier M, Guigue P, Pagès C, et al,. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153: 66-7.
30. Griffiths CE, Christophers E, Barker JN, et al,. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-62.
31. Di Meglio P, Villanova F, Napolitano L, et al,. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol 2013; 133: 2381-9.
32. Feng BJ, Sun LD, Soltani-Arabshahi R, et al,. Multiple loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 2009; 5: e1000606.
33. Knight J, Spain SL, Capon F, et al,. Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Hum Mol Genet 2012; 21: 5185-92.
34. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium, Strange A, Capon F, et al,. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985-90.
35. Agarwala V, Flannick J, Sunyaev S, et al,. Evaluating empirical bounds on complex disease genetic architecture. Nat Genet 2013; 45: 1418-27.
36. Lee JC, Espéli M, Anderson CA, et al,. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013; 26: 57-69.
37. Talamonti M, Botti E, Galluzzo M, et al,. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013; 169: 458-63.
38. Mahil SK, Arkir Z, Richards G, et al,. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single centre, cohort study. Br J Dermatol 2013; 169: 306-13.
39. British Association of Dermatologists. Biologic Interventions Register. Available at: www.badbir.org (last accessed 4 May 2014).
40. PSORT. Psoriasis Stratification to Optimise Relevant Therapy. Available at: www.psort.org.uk (last accessed 4 May 2014).